NUVB רווח למניה בשנים עשר החודשים האחרונים Nuvation Corp

The absence of regular cash inflows due to the testing stage makes Nuvation Bio Inc. (NUVB) dependent on its existing capital. The change in the rolling annual EPS on GURU.Markets reflects the current trend, where -0.39 is recorded as the baseline value. This occurs amid an expansion into targeted oncology following the deal with AnHeart and high market demand for solid tumor treatments.

This indicator measures the equity value of the business via net income per share on a trailing twelve-month (TTM) basis, reflecting the issuer's actual financial return. By analyzing the change in TTM net income per share, an investor can see the impact of oncology drug development costs for Nuvation Bio Inc. (NUVB), where current negative values are justified by investments in intellectual property for future monetization.